{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-316607","form_type":"8-K","ticker":null,"cik":"0001697532","company_name":"Applied Therapeutics, Inc.","filed_at":"2025-12-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.172400+00:00","generated_at":"2026-05-16T13:21:59.292851+00:00","sec_items":["1.01","2.03","7.01","9.01"],"event_type":"m_and_a","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Applied Therapeutics to be acquired by Cycle Group for $0.088/share plus CVRs worth up to $0.40","bullets":["Offer price: $0.088 per share cash plus one non-tradeable CVR with up to $0.40 per share in milestone payments.","Milestones include FDA approval for galactosemia ($0.10), CMT-SORD ($0.10), and net sales >= $200M ($0.20).","Parent provides up to $8.5M unsecured promissory note at 24% interest to fund working capital pending close.","Board unanimously approved; transaction subject to tender of majority of shares and other customary conditions.","Termination fee of $648,000 plus 4.5% of outstanding note principal payable by Applied in certain circumstances."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-316607","json":"https://secwatch.observer/filing/0001193125-25-316607.json","markdown":"https://secwatch.observer/filing/0001193125-25-316607.md","text":"https://secwatch.observer/filing/0001193125-25-316607.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1697532/000119312525316607/0001193125-25-316607-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1697532/000119312525316607/d41524d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T13:21:59.292851+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d9e60b0a434a03ec3b44c367d3623d0a93fe764b","claim":"Applied Therapeutics, Inc. incurred loan of not fully specified in excerpt with not fully specified in excerpt at not fully specified in excerpt maturing not fully specified in excerpt.","evidence_excerpt":"Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth in Item 1.01 of this report under the caption titled “Unsecured Promissory Note,” including Exhibit 10.1 attached hereto, is incorporated by reference in this Item 2.03.","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1697532/000119312525316607/0001193125-25-316607-index.htm","confidence":0.6,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"loan"},{"label":"Principal","value":"not fully specified in excerpt"},{"label":"Counterparty","value":"not fully specified in excerpt"},{"label":"Rate","value":"not fully specified in excerpt"},{"label":"Maturity","value":"not fully specified in excerpt"},{"label":"Event","value":"incurrence"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}